Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10

NCT03294707 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyloid Cardiomyopathy, Transthyretin-Related

Interventions

DRUG: AG10 oral tablet
DRUG: Placebo Oral Tablet

Sponsor

Eidos Therapeutics, a BridgeBio company

Collaborators

[object Object]